Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal … – Markets Insider
|
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal …
Markets Insider CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today presented … Intellia Therapeutics, Inc. (NTLA) Lifted to “Hold” at ValuEngineDispatch Tribunal |
|
International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and …
Markets Insider “ISCO was one of the first stem cell biotech companies to build a business model in which revenue-generating subsidiaries operate under a parent R&D company. This not only decreases cash burn while conducting our Parkinson’s disease clinical trial, but … |
Endpoints News |
Next-gen CAR–T, TCR player Autolus gains $80M for clinical trial work
Endpoints News Autolus is one of a number of upstart biotechs that think better technology — like its pattern recognition tech — can make for a much better CAR-T or T cell receptor therapy personalized for each patient. These new cell therapies, they believe, will … AUTOLUS LIMITED: Autolus Secures US$80 million Series C FundingGlobeNewswire (press release) Syncona leads $80 mln round for gene therapy firm AutolusReuters |
|
Could Engineered Bacteria Implanted into Human Skin Produce Insulin?
A Sweet Life Microscopic organisms can do amazing stuff. Yeast is instrumental in baking bread and brewing beer. Bacteria make yogurt. And now, thanks to synthetic biology, they might be the key that unlocks a revolutionary treatment for type 1 diabetes. “Bacteria … |
|
International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and …
GlobeNewswire (press release) “ISCO was one of the first stem cell biotech companies to build a business model in which revenue-generating subsidiaries operate under a parent R&D company. This not only decreases cash burn while conducting our Parkinson’s disease clinical trial, but … |